Insider Selling: Global Blood Therapeutics Inc (NASDAQ:GBT) Insider Sells 2,765 Shares of Stock

Share on StockTwits

Global Blood Therapeutics Inc (NASDAQ:GBT) insider Lesley Ann Calhoun sold 2,765 shares of the business’s stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $54.36, for a total value of $150,305.40. Following the transaction, the insider now directly owns 887 shares of the company’s stock, valued at approximately $48,217.32. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Global Blood Therapeutics stock traded down $0.27 during trading hours on Friday, hitting $54.04. The stock had a trading volume of 739,100 shares, compared to its average volume of 781,103. The company has a 50-day moving average of $49.97 and a two-hundred day moving average of $54.43. The company has a quick ratio of 16.79, a current ratio of 16.79 and a debt-to-equity ratio of 0.03. The company has a market cap of $3.25 billion, a PE ratio of -15.85 and a beta of 1.58. Global Blood Therapeutics Inc has a fifty-two week low of $30.15 and a fifty-two week high of $64.94.

Global Blood Therapeutics (NASDAQ:GBT) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.96) by ($0.05). During the same quarter in the previous year, the business earned ($0.78) earnings per share. As a group, analysts forecast that Global Blood Therapeutics Inc will post -3.98 EPS for the current fiscal year.

A number of institutional investors have recently bought and sold shares of the business. Luminus Management LLC acquired a new position in Global Blood Therapeutics in the 2nd quarter valued at approximately $20,368,000. Magnetar Financial LLC acquired a new position in shares of Global Blood Therapeutics in the 2nd quarter worth approximately $1,578,000. Perceptive Advisors LLC raised its holdings in shares of Global Blood Therapeutics by 4.5% in the 2nd quarter. Perceptive Advisors LLC now owns 5,775,726 shares of the company’s stock worth $303,803,000 after buying an additional 250,000 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. raised its holdings in shares of Global Blood Therapeutics by 6,110.0% in the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 4,968 shares of the company’s stock worth $261,000 after buying an additional 4,888 shares in the last quarter. Finally, United Services Automobile Association raised its holdings in shares of Global Blood Therapeutics by 1.3% in the 2nd quarter. United Services Automobile Association now owns 65,201 shares of the company’s stock worth $3,430,000 after buying an additional 863 shares in the last quarter. 97.99% of the stock is owned by hedge funds and other institutional investors.

Several equities analysts recently weighed in on GBT shares. Cowen set a $83.00 price objective on Global Blood Therapeutics and gave the stock a “buy” rating in a research report on Thursday, September 5th. BidaskClub raised Global Blood Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, September 6th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Global Blood Therapeutics in a report on Thursday, September 5th. Goldman Sachs Group reaffirmed a “neutral” rating and issued a $75.00 price target on shares of Global Blood Therapeutics in a report on Wednesday, May 29th. Finally, Wedbush reaffirmed a “buy” rating and issued a $120.00 price target on shares of Global Blood Therapeutics in a report on Thursday. One analyst has rated the stock with a sell rating, three have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $89.75.

About Global Blood Therapeutics

Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.

Further Reading: What is a good rate of return for a mutual fund?

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.